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Introduction
Inherited mitochondrial diseases have long been regarded as severe multi-system disorders associating many neurological symptoms. In most cases, they involve alterations of subunits of the respiratory chain complexes, as is the case for example in Leigh syndrome (Bugiani et al., 2004) . This paradigm was questioned by the identification of mutations in genes encoding proteins involved in the mitochondrial dynamics, which participate and control the mechanisms of fusion and fission of the outer and inner mitochondrial membranes (Bertholet et al., 2016) . Central to this process are a set of five large GTPases related to dynamins, which either pinch and fission the membranes, as DNM1L/DRP1 and DNM2, or conversely associate and fuse them, as OPA1 and MFN1/2 (Kuroiwa et al., 2006) . Tight regulation of these processes is crucial for the CNS and peripheral nervous system, as mutations in these genes have been identified originally in severe encephalopathies for DNM1L (MIM *603850; Waterham et al., 2007) , in dominant optic atrophy (DOA) for OPA1 (MIM *605290; Alexander et al., 2000; Delettre et al., 2000) , in Charcot-Marie-Tooth type 2M for DNM2 (MIM *602378; Zuchner et al., 2005) , and type 2A for MFN2 (MIM *608507; Zuchner et al., 2004) , whereas no mutation has yet been reported in MFN1. More recently, with the advent of the exome sequencing, novel mutations in these genes or different modes of transmission have been correlated to alternative clinical presentations, such as the Behr syndrome for OPA1 (Bonneau et al., 2014) and the hereditary motor and sensory neuropathy VIA for MFN2 (Zuchner et al., 2006) , suggesting that different pathophysiological mechanisms and/or different severity of the mutations can modulate the symptoms and define the clinical outcomes.
Since the identification of the first OPA1 mutations in DOA (Alexander et al., 2000; Delettre et al., 2000) , we have identified mutations in other dominant OPA3, MFN2 and AFG3L2, and recessive TMEM126A, ACO2, RTN4IP1 and NDUFS2 genes in inherited optic neuropathies (Reynier et al., 2004; Hanein et al., 2009; Rouzier et al., 2012; Metodiev et al., 2014; Angebault et al., 2015b; Charif et al., 2015; Gerber et al., 2017) . Nevertheless, the screening of these genes in our cohort of DOA individuals only led to $50-60% of molecular diagnosis, prompting us to solve the unsolved cases. Using next generation sequencing, we identified three families with isolated DOA and novel heterozygous DNM1L mutations, and observed an excess of mitochondrial fusion in cells from affected individuals. Interestingly, this excess of mitochondrial fusion caused by DNM1L mutations leads to a clinical presentation indistinguishable from the one induced by the excess of mitochondrial fission caused by OPA1 mutations.
Materials and methods
Written informed consent from affected and control individuals or from the parents of subjects under 18 years of age was obtained to perform genetic and pathophysiological studies, according to protocols approved by Ethical Committees of the different Institutes involved in this study, and in agreement with the Declaration of Helsinki.
Genetic analysis Family I
Whole exome sequencing was performed on 20 probands from unresolved DOA families, using Agilent V5, 51 Mb exome enrichment kit, followed by Illumina HiSeq2000, 30Â coverage sequencing. After excluding intronic, 5'UTR, 3'UTR and synonymous variants, data were filtered for unknown heterozygote non-synonymous mutations in genes encoding mitochondrial proteins (MitoCarta). In one proband (Family I), a novel mutation in DNM1L was identified, confirmed by Sanger sequencing and its segregation established on all available DNA samples from the family.
Families II and III
Families II and III were previously referred to as Families A and B, respectively, in Barbet et al. (2005) and were unsuccessfully screened for mutations at the OPA5 locus (MIM610708) using Sanger sequencing of all coding regions and intron-exon boundaries of genes lying within the 10.4 Mb interval. Thus, the genomic DNA (1 mg) of affected Subjects II:7, III:1, III:2, III:3 and III:5 of Family II were sequenced using the HiSeq 2000 (Illumina) at the Genomic Core Facility of Imagine (Paris). Libraries were prepared using the SureSelect Human All Exon Kit v3 (Agilent Technologies) according to manufacturer's protocols and run in pair ended mode (2 Â 75). Image analysis and base calling were performed with Real Time Analysis (RTA) Pipeline version 1.9 with default parameters (Illumina). Sequences were aligned to the human genome reference sequence (UCSC Genome Browser hg19 assembly), and single nucleotide polymorphisms were called on the basis of allele calls and read depth with the use of the Consensus Assessment of Sequence and Variation pipeline (v.1.8, Illumina). Genetic variation annotation was performed by an in-house pipeline. Only the variants whose positions were covered 510Â were further considered. In the light of the non-ambiguous autosomal dominant inheritance of the disease in Family II with several father-to-son transmissions, we selected heterozygous variants with a minor allele frequency 50.1% shared by all the affected members. The pathogenicity of the selected variants was assessed using the Alamut Mutation Interpretation Software (http://www.interactive-biosoftware.com), a decision support system for mutation interpretation based on Align DGVD, MutationTaster, PolyPhen-2, SIFT, SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer, Human Splicing Finder, ESEfinder and RESCUE-ESE.
After the identification of the mutation in Families I and II, DNM1L (NM_012062.3) coding exons and intron-exon junctions were amplified from genomic DNA from the index case of Family III, using 20 primer pairs designed from introns and non-coding sequences (5' and 3'), respectively (primer sequences and PCR conditions available on request). Amplified fragments were purified and sequenced using the fluorescent dideoxy-terminator method on an automatic sequencer (ABI3100, Applied Biosystems). The pathogenicity of variants was assessed using the Alamut Mutation Interpretation Software.
Haplotyping of the DNM1L locus in Subjects II:6 (Family I) and II:7 (Family II) sharing the c.5A4C mutation Three markers containing short tracks of (CA)n repeats flanking the DNM1L locus (12p11.21) were chosen from the Human genome sequence available at UCSC (GRCh37/hg19; www.genome.ucsc.edu) on the basis of their position and informativity: AFMB013YB1, AFM296YG5 and AFM092WD11 at the D12S1643, D12S345 and D12S331 loci, respectively. The markers were amplified from genomic DNA and analysed on an automatic sequencer (ABI 3500XL, Applied Biosystems). Primer sequences and experimental conditions are available at UCSC and on request, respectively. Alleles were called using the GeneMapper Software 5 (Applied Biosystems) and haplotypes were built manually.
Fibroblast cultures
Fibroblasts from Patients P1:III:6, P2:III:3 and P3:II:7 from Families I, II and III, respectively, were generated and cultured from skin biopsies. Cells were cultivated in two-thirds Dulbecco's modified Eagle medium (DMEM, Gibco) supplemented with onethird AmnioMAX TM (Gibco), 10% foetal calf serum (Lonza) and 1% Penicillin-Streptomycin-Amphotericin B (Lonza).
Western blot analysis
For fibroblasts, frozen pellets were resuspended in phosphatebuffered saline (PBS) and the cellular protein content was determined with the Bicinchoninic acid assay kit (Thermo Scientific). Forty micrograms of total protein were separated on a 10% SDS-polyacrylamide gel and electro-blotted onto a PVDF membrane (Bio-Rad). Membranes were saturated with 5% non-fat milk dissolved in TBS-Tween 0.1% (pH 7.4, NaCl 137 mM, KCl 2.7 mM, Tris 23 mM, Tween 0.1%) for 1 h at room temperature and incubated overnight at 4 C with monoclonal mouse anti-DNM1L (Abcam, ab56788; 1:500), and rabbit anti-OPA1 (Abcam ab42364; 1:1000), mouse anti-MFN2 (Abcam ab56889; 1:1000) and rabbit anti -Tubulin (Abcam ab52866; 1:10 000). Membranes were then washed three times in TBS-Tween 0.1% and incubated with antimouse IgG horseradish peroxidase linked antibody (Amersham Biosciences, NXA931; 1:20 000) for 1 h at room temperature. The immune-reactive proteins were visualized with enhanced chemiluminescence (ECL Prime Western Blotting Detection Reagents, Amersham Biosciences). Band intensities were quantified with Image Studio 2.1 software (Li-Cor, Lincoln, NE, USA).
Mitochondrial purification and assessment of DNM1L oligomerization by blue native PAGE Cells were washed with cold PBS and detached using a cell scraper. The suspension was centrifuged at 900 g, 4 C for 10 min, and the pellet resuspended and incubated 10 min at 4 C in 3 ml of ice-cold mitochondrial isolation buffer (0.1 M Tris-MOPS and 1 ml of EGTA/Tris to 20 ml of 1 M sucrose) before being placed in a glass potter and stroked 30-40 times. Broken cells were then centrifuged at 1000g to discard the nuclei and at 20 000g for 5 min at 4 C to recover the mitochondrial fraction. Following the centrifugation steps, the protein content of both the cytosol and the pellet were measured using BCA Protein Assay Kit (Uptima). Mitochondrial proteins (25 mg) were suspended in aminocaproic acid tris buffer for a final volume of 25 ml and 75 mg of lauryl-maltoside were added to samples which were then incubated under agitation for 10 min at 4 C. Samples were centrifuged at 20 000g for 20 min at 4 C, and the supernatant along with the initial cytosolic fraction were submitted to blue native polyacrylamide gel electrophoresis (BN-PAGE) in 3-12% gels. The gel was electron-transferred on a PVDF membrane. After blocking for 1 h with 5% milk in tris-buffered saline with 0.2% Tween-20, the membrane was probed with mouse anti-DNM1L antibody and mouse anti-SDHA antibody (Abcam ab14715; 1:1000). Antimouse peroxidase-linked secondary antibody (GE Healthcare, Life Sciences) was used at 1:10 000 and signals were detected using a chemiluminescence system (Super signal Õ West Femto, Thermo Scientific, #34095) (Thermo Fisher Scientific). The images acquired were analysed quantitatively as for western blots.
Immunofluorescence and imaging
Cells were fixed using 4% paraformaldehyde (PFA) for 20 min at room temperature and rinsed twice with PBS. Cells were permeabilized using a blocking solution containing 0.1% Triton X-100 5% BSA donkey serum in PBS. Primary antibodies included rabbit antibody to citrate synthase (Abcam ab96600; 1:1000) and DNM1L were incubated with fixed cells overnight at 4 C. Primary antibodies were visualized using Alexa Fluor Õ 488-or Alexa Fluor Õ 647-labelled secondary antibodies at a dilution of 1:1000 (Jackson ImmunoResearch). After 2 h incubation, cells were rinsed twice with PBS for 10 min and mounted on coverslips using Fluorescence Mounting Medium (Dako, S3023). Images were captured with an AxioImager microscope (Zeiss). Cell counting and analyses were performed using the Imaris software (NIH).
Deconvolution microscopy and mitochondrial network analysis
Mitochondria were labelled using 100 nM Mitotracker Õ Green (Molecular Probes). For imaging, coverslips were mounted in a Cytoo Õ incubation chamber placed on the stage of an inverted microscope. Images were acquired with an inverted wide-field Leica microscope (Microsystems) equipped with a high-sensitivity Roper CoolSnap HQ2 (Roper Scientific) CCD camera. A precision, piezoelectric driver mounted underneath the objective lens allows faster Z-step movements, keeping the sample immobile while shifting the objective lens. An average of 30 image planes was acquired along the z-axis at 0.2 mm increments. A mean of 80 cell acquisitions from two different micropatterned slides were used for each cell type and condition. Metamorph Õ 7.7 software (Molecular Devices) was used for image acquisition. Image restoration algorithms were used to reassign the optical blur to its original location (Scientific Volume Imaging). Imaris 7.1.1 Õ software (Bitplane) was used for 3D processing and morphometric analysis.
Peroxisome network assessment
Cells were fixed using 4% PFA in PBS for 15 min and permeabilized in 0.5% Nonidet TM (Roche Diagnostics). The cells were saturated in blocking buffer containing 2% bovine serum albumin (BSA) and 1% Tween-20 in PBS for 20 min, then incubated overnight at 4 C with the primary rabbit polyclonal PMP70 antibody (Novus NBP1-87258; 1:500). Bound targeted proteins were visualized with the following secondary antibody: Alexa Fluor Õ 568-labelled-goat anti-rabbit IgG, (ab175471; 1:1000). Cell nuclei were stained using Hoechst 33342 (Molecular Probes; 1:2000). The cells were then sealed using antifade mounting medium (Invitrogen) and visualized using the inverted wide-field Nikon Ti-E microscope equipped with and Andor NEO sCOMS camera controlled by NIS Element software.
Enzymatic activities and protein content
The activity of the mitochondrial respiratory chain complexes was measured on cell homogenates in a cell buffer (250 mM saccharose, 20 mM tris[hydroxymethyl]aminomethane, 2 mM EGTA, 1 mg/ml bovine serum albumin, pH 7.2), at 37 C using a UVmc 2 spectrophotometer (SAFAS). The cellular protein content was determined with the Bicinchoninic acid assay kit (Thermo Scientific). Complex I-V and citrate synthase enzymatic activities were measured by standard procedures (Angebault et al., 2015a) .
Oxygen consumption
Respiratory rates were measured on digitonin-permeabilized cells in a specific buffer (pH 7.4, 10 mM KH 2 PO4, 300 mM mannitol, 10 mM KCl, and 5 mM MgCl 2 ). The respiratory rates of 3-5 Â 10 6 cells were recorded at 37 C in 2 ml glass chambers using a high-resolution oxygraph respirometer (Oroboros). Respiration was started with complex I-dependent substrates (5 mM malate / 5 mM pyruvate). Complex I-coupled state 3 respiration was measured by adding 0.5 mM NAD + / 1.5 mM ADP. Then, 10 mM succinate was added to reach maximal coupled respiration, and 10 mM rotenone was injected to obtain the complex II-coupled state 3 respiration. Oligomycin (8 mg/ml) was added to determine the uncoupled state 4 respiration. Finally, FCCP (1 mM) was added to control the permeabilization of the fibroblasts.
Animal breeding
All experiments were performed in accordance with the European Community Guiding Principles for the care and use of animals (Directive 2010/63/UE; Décret n 2013-118). Details of the construction of the Dnm1l + /À mouse model and its phenotypic characterization have been previously published (Wakabayashi et al., 2009 ).
Immunohistochemical analysis on mouse retina
For DNM1L immunohistochemistry, we prepared 7 -mm thick wax sections of wild-type mouse retina (Bonnet Wersinger et al., 2014) . Sections were fixed in cold 4% PFA for 20 min at room temperature, washed with PBS, permeabilized by 0.1% Triton TM X-100/PBS for 10 min at room temperature and washed with PBS. Next, tissues were incubated with 0.5% blocking solution (BSA/PBS) for 1 h at room temperature, then with the primary antibody DNM1L (1:500) overnight at 4 C. After several washes, sections were incubated with Alexa Fluor Õ 594-labelled secondary antibodies at a dilution of 1:1000 for 1 h at 4 C and then washed with PBS. Finally, sections were incubated with Hoechst 33342 (1 mg/ml) for 5 min at room temperature. Images were captured with an AxioImager microscope (Zeiss).
Transmission electron microscopy
Following enucleation, mouse eyes and optic nerves were immediately immersed in 2.5% glutaraldehyde solution. Cornea was then removed to allow diffusion of the glutaraldehyde to the retina. Fixation was realized over 20 h. Optic nerves and retina were cut and prepared for transmission electron microscopy (TEM) staining. Preparations were observed using a transmission electronic microscope (JEM1400, JEOL). Pictures were acquired using either 12K or 30K magnification. Five 3-month-old animals were used in each group.
The total number of axons was counted using TEM observation. Five pictures of transversal section of optic nerves were evaluated under Â 12K magnification. Total number of axons per optic nerve was calculated using the number of axons per mm 2 and the total surface of the transversal section measured in optic microscopy.
Length of mitochondria was evaluated using Fiji software. The long axis of mitochondria was measured in at least 10 pictures of transversal section of the retina or optic nerve under Â30K magnification.
Results

Identification of DNM1L pathogenic variants in individuals with dominant optic atrophy
Routine screening of the OPA1, OPA3 and WFS1 exonic sequences and of the three main mitochondrial mutations responsible for the Leber hereditary optic neuropathy was performed on DNA samples from a large cohort of DOA subjects. Cases without positive result, including subjects from one of the two original OPA5 families (Family II), were analysed by whole exome sequencing. Results were filtered for unknown deleterious mutations and compared among the whole cohort of individuals. The same monoallelic unreferenced mutation in DNM1L (NM012062.3; NP_036192), located on chromosome 12p11.21: c.5A4C, was found in Families I and II. No other candidate variant was identified, including at the OPA5 locus on chromosome 22q12.1-q13.1, questioning the existence of the locus. Segregation of the c.5A4C mutation among the two families perfectly fitted with the clinical status of the 13 affected individuals, for whom DNA samples were available (Fig. 1A) . Segregation analysis of markers flanking the mutation suggests a founder effect by showing the transmission of a common haplotype with the disease in the tested individuals of the two families (Supplementary Table 1 ). Sanger screening of DNM1L exons and intron boundaries in the second original OPA5 family (Family III, previously referred to as Family B; Barbet et al., 2005) identified another monoallelic unreferenced mutation c.575C4A, whereas sequence analysis of 82 additional unrelated index cases detected no additional mutation. The c.575C4A mutation fully segregated with the disease in Family III (Fig. 1A) , whereas no mutation was found by Sanger screening of genes at the OPA5 locus, strongly supporting the involvement of DNM1L and withdrawing in corollary the OPA5 locus. The c.5A4C and c.575C4A mutations induce the p.E2A and p.A192E changes, respectively, affecting two highly conserved amino acids from the DNM1L GTPase domain (Fig. 1B) , and affecting peptides that are highly intolerant to damaging mutation ( Supplementary Fig. 1A ). Both are predicted to be damaging by PolyPhen-2 (score: 0.995 and 0.964), SIFT (score: 0 and 0) and MutationTaster (score 107 and 107). These amino acid changes are the only missense mutations reported to date in the DNM1L GTPase domain; the others were either stop codons truncating the protein from the GTPase domain onwards, or missense mutations affecting the Middle domain (Fig. 1C , Table 2 and Supplementary Fig. 1B ). In addition, the two mutations identified here in DOA cases are the first dominantly inherited mutations reported, as previous DNM1L mutations were either dominant de novo or recessive mutations leading to severe neurological presentations.
Clinical examination of DNM1L mutated individuals
Four of five mutation carriers from Family I were examined (Table 1) . Visual acuity was decreased in Subjects III.5 and (Table 2) , and the two identified in this study (in red). III.6, and normal in the younger Subjects IV.4 and IV.6 and the visual field from Subjects III.6, IV.4 and IV.6 revealed a relative central scotoma. There were moderate colour vision errors in Subjects III.5 and IV.6. Fundus examination revealed a symmetrical temporal pallor of the optic disc in the four affected individuals (Fig. 2 ). All of them had a reduction of retinal nerve fibre layer thickness around the optic nerve head in all quadrants predominating in temporal (Fig. 2) . Visual evoked potentials were moderately to severely impaired. Importantly, neurological examination did not disclose any additional symptom, but Subject III.5 had moderate hearing loss (Table 1) . Ophthalmic examination of Family I members without the mutation (Subjects IV.1, IV.2, IV.3 and IV.5) was normal. Clinical description of individuals from Families II and III were reported in a previous study, which, based on genetic studies of these two families, identified the OPA5 locus as a candidate DOA locus. All patients from these families were described with a phenotype similar to that of OPA1-related DOA, without additional symptoms. Follow-up of these patients in the last years did not disclose additional symptoms. Besides, metabolic work-up, neurological examination, 3 T cerebral MRI with spectroscopy, audiogram and auditory evoked potentials recordings and cardiac echo-sonography in Subjects II7, III4 (Family II) and III3 (Family III), aged 75, 46 and 38 years, respectively, detected no sign consistent with mitochondrial dysfunction. Thus, in this respect, the two dominant inherited mutations in DNM1L identified in the present study are responsible for this non-syndromic mild DOA presentation, indistinguishable from that induced by the majority of OPA1 mutations.
DNM1L mutated fibroblasts show a hyperfused mitochondrial network without peroxisome alteration
We analysed fibroblasts from one affected individual from each family (Subjects III:6, III:3 and II:7 from Families I, II and III, respectively), compared to three control fibroblasts. In mutant fibroblasts, Western blot showed that DNM1L expression level together with that of OPA1 and MFN2 are similar in the pathological and control conditions, disclosing that the mutated protein is expressed and may act as a dominant negative allele (Fig.  3A) . Exploration of DNM1L capacity to homopolymerize in cytoplasmic and mitochondrial fractions did not reveal difference (Fig. 3B) , suggesting that the mutated protein might interact with the wild-type protein and consequently impair homopolymer activity. Immunofluorescence analysis of mutated cells, using DNM1L antibodies, revealed that DNM1L forms aggregates localized both in the cytoplasm and on the mitochondrial network, while DNM1L aggregates were more abundant on the mitochondrial network of control cells (Fig. 3C) . Importantly, if all the steps related to DNM1L activity on the mitochondrial fission sites (clustering on mitochondria, forming pair of clusters then helical rings around mitochondria, to end with dots at the fission extremities) could be observed in wild-type Figure 2 Ophthalmological exploration of DNM1L affected individuals. Eye fundus pictures of affected (Subjects III:5, III:6, IV:4 and IV:6) and unaffected (Subject IV:5) cases from Family I reveal a symmetric temporal pallor of the optic discs, except in the unaffected patient (Subject IV:5). Retinal nerve fibre layer assessment (RNFL: bottom left) by optic coherence tomography (OCT) in Subject III.6 shows a reduced RNFL thickness in all quadrants, in particular on the temporal (TMP), superior (SUP) and inferior (INF) sides, while less on the nasal (NAS) side. The green area defines the 5th to 95th, the yellow area the 1st to 5th and the red area below the first percentiles.
conditions using super-resolution imaging, in mutated fibroblasts, many DNM1L clusters were not associated with mitochondrial constriction sites ( Supplementary Fig.  2 ), suggesting an impairment of the fission process. In line with these observations, assessment of mitochondrial structures using MitoTracker, revealed a highly elongated network with a 2.5-fold decrease of the number of mitochondrial extremities in mutated cells (Fig. 3D) . Because DNM1L activity is also involved in peroxisome division (Schrader 2006) , we assessed the structure of the peroxisomal network using PMP70 antibodies, but failed to evidence any difference between mutated and control cells (Fig. 3E) . Measurement of the respiratory parameters in both conditions did not reveal a difference (Supplementary  Table 2 ). Thus the DNM1L mutations identified here induce a restricted dominant negative effect on mitochondrial fission, resulting in a highly elongated mitochondrial network.
DNM1L expression and function in mouse retinal ganglion cells
To gain further insights in the pathological mechanism, we analysed the expression of DNM1L in the retina from wild-type mice by immunofluorescence. A faint labelling was observed in all plexiform layers, while in the ganglion cell layer, DNM1L expression was pre-eminent (Fig. 4A) , as eventually in the pigmentary epithelium and the choroid. We then assessed the consequence of DNM1L alteration in a mouse model bearing a knock-out allele of Dnm1l/Drp1 (left) showing the labelling of the peroxisome network, using PMP70 antibody, and histogram (right) assessing the fluorescence associated to the peroxisomes on control (top) and patient (bottom) fibroblasts. All values were obtained from three experiments performed on three control and three mutated skin fibroblasts. For cell biology imaging, they represent means AE SEM of at least 40 measurements from two independent acquisitions. **P 5 0.01, Mann-Whitney U-test. Scale bar = 10 mm in C left, D and E; and 3 mm in C right. (Wakabayashi et al., 2009) . In 3-month-old animals, assessment of the axon number on trans-sections of the optic nerve did not reveal differences between mutated and control animals (Fig. 4B ). TEM observations of transversal sections of the retina and longitudinal sections of the optic nerve disclosed a significant increase in mitochondrial length in heterozygous animals, which was not accompanied by further deleterious features in the optic nerve (Fig.  4C) , in the line with previous observations (Manczak et al., 2012) . Thus, in 3-month-old Dnm1l + /À animals, the mitochondrial network of retinal ganglion cells is elongated, although without axonal degeneration.
Discussion
Isolated optic neuropathies are amongst the most frequent rare diseases affecting sight. Frequently, they are transmitted in a dominant mode of inheritance by OPA1 mutations that hamper mitochondrial fusion. The identification here of heterozygous DNM1L mutations in individuals of three families with non-syndromic optic neuropathies strongly suggests that mitochondrial fission is also crucial for the maintenance of the optic nerve physiology and survival. Of note, two of the three families (Families II and III) were previously mapped on 22q12.1-q13.1, but no mutated gene was found (Barbet et al., 2005) . The two missense p.E2A and p.A192E changes presented here are the first dominantly inherited mutations affecting the GTPase domain of this dynamin to be described. Indeed so far, all the other reported DNM1L mutations were heterozygous de novo mutations affecting the middle domain, or recessive nonsense mutations leading to truncated unstable protein (Fig. 1) . One exception concerns the p.S36G amino acid change that also affects the GTPase domain, identified in a recessive family. Nevertheless, in all cases previously reported, DNM1L patients had early-onset severe syndromic neurological presentations including epilepsy and/or encephalopathies, sometimes related to developmental abnormalities ( Table 2) . The 16 patients that we clinically examined in this study had mild non-syndromic optic atrophy similar to what is found in cases with OPA1 mutations, except for one individual (Family I, Subject III:5) who also had moderate hearing loss (30 dB), a feature that is also regularly reported in a small proportion of OPA1 patients (Leruez et al., 2013) . Indeed, as observed in Family I, visual acuity was not severely decreased, and there was a relative central scotoma, as found in many patients with OPA1 mutations. In addition, the loss of retinal nerve fibre layer was less severe as in autosomal recessive cases (Grenier et al., 2016 ). Yet, we found that the disease was progressive in the three families, also as generally observed in OPA1 DOA (Cohn et al., 2008) . This suggests that even though OPA1 and DNM1L have opposite effects on the mitochondrial network, the pathogenic consequences are the same, suggesting a similar pathway leading to retinal ganglion cell death, stressing further therapeutic applications.
Analysis of fibroblasts from affected individuals from the three families did not disclose alteration of the mitochondrial respiration, nor of the peroxisome network, while it clearly evidenced a hyperfilamentous mitochondrial network, disclosing a severe mitochondrial fission defect. As the amount of DNM1L protein was physiological in all patients' fibroblasts, forming aggregates in the cytoplasm and on unconstricted tubular mitochondria, we deduced that both mutations act as dominant negative, impairing the DNM1L pinching activity required for network fission, while maintaining its capacity to form homopolymers on the outer mitochondrial membrane. A similar phenotype with elongated mitochondria was observed in the optic nerve and retinal ganglion cell layer from 3-month-old Dnm1l + /À mice, although without evidencing any sign of axonal degeneration (Manczak et al., 2012) . This parallels our observations on the Opa1 + /À mouse model, which does not reveal optic nerve structural or functional alteration at 3 months of age (Sarzi et al., 2012 (Sarzi et al., , 2016 . Nevertheless, we cannot exclude that mice with a Dnm1l dominant-negative mutation could reveal a stronger and earlier phenotype than the one associated to Dnm1l haploinsufficiency studied here.
To conclude, the identification of two inherited DNM1L dominant mutations not only points to a novel gene responsible for non-syndromic DOA and withdraws the OPA5 locus, but it also points to a novel pathophysiological mechanism specifically responsible for retinal ganglion cell degeneration, most likely different from the one responsible for early onset encephalopathies caused by the other mutations identified in this gene ( Table 2 ). The DNM1L function being opposite to that of OPA1, our results suggest that retinal ganglion cells are exquisitely sensitive to disequilibrium between the fusion and fission forces, which regulate mitochondrial membrane dynamics.
